A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2016
At a glance
- Drugs Vismodegib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 02 Oct 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 22 May 2013 Planned initiation date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 25 Mar 2013 Planned initiation date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.